Coronary artery disease (CAD) is the most common cardiovascular disease, while atrial fibrillation (AF) is the most frequent type of cardiac arrhythmia. These pathologies possess common risk factors, such as hypertension, diabetes mellitus, sleep apnea, obesity and smoking. Moreover, inflammation is essential for the development of both diseases. The prevalence of CAD in patients with AF ranges from 17 to 46.5%, while the prevalence of AF in patients with CAD is relatively low and is estimated to be only 0.2–5%. AF is a known factor of unfavorable short-term and long-term prognosis in patients with acute myocardial infarction (AMI) and is associated with a significant increase in overall mortality. Cardiac arrhythmias are not infrequent after cardiac surgery and occur in approximately 30–40% of patients undergoing coronary artery bypass surgery. It is estimated that 5–15% of patients with AF will ever require percutaneous coronary intervention and, subsequently, triple antithrombotic therapy with aspirin, clopidogrel or ticagrelor and oral anticoagulant. This demands a very careful consideration of balanced antithrombotic therapy, taking into account the high risk of bleeding, the risk of stroke and stent thrombosis with subsequent acute coronary syndrome. The concomitant administration of oral anticoagulants with antiplatelet drugs, and, particularly, the triple therapy, significantly increases the absolute risk of serious bleeding. In addition, heavy bleeding is associated with a five-fold increase in the risk of an adverse outcome after acute coronary syndrome. The co-presence of AF and CAD worsens the prognosis even in patients undergoing thorough treatment.

coronary artery disease; atrial fibrillation; prevention; antithrombotic therapy.

Bockeria, L.A., Yarbekov, R.R., Sigaev, I.Yu., Chigogidze, N.A., Merzlyakov, V.Yu. and Keren, M.A. (2014). Comparison of long-term outcomes of coronary artery bypass grafting and percutaneous coronary intervention using drug-eluting stents in patients with multivessel coronary artery disease and diabetes mellitus. Cardiovascular Diseases. Bulletin of Bakoulev Center for Cardiovascular Surgery, 15(5), pp.37–45. (In Russian)

Kirchhof, P., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B. et al. (2016). 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal, 37(38), pp.2893–2962. https://doi.org/10.1093/eurheartj/ehw210

National Heart, Lung, and Blood Institute. (2012). Morbidity and Mortality: 2012 Chart Book on Cardiovascular, Lung, and Blood Diseases. Bethesda, MD.

Naghavi, M., Wang, H., Lozano, R., Davis, A., Liang, X., Zhou, M. et al. (2015). Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. The Lancet, 385(9963), pp.117–171. https://doi.org/10.1016/S0140-6736(14)61682-2

Bockeria, L.A. and Shengelia, L.D. (2014). Treatment of atrial fibrillation. Part II: Current realities and future prospects. Annals of Arrhythmology, 11(2), pp.76–86. https://doi.org/10.15275/annaritmol.2014.2.2 (In Russian)

Bockeria, O.L., Akhobekov, A.A., Shvarts, V.A. and Kudzoeva, Z.F. (2015). Efficacy of statins in primary prevention of atrial fibrillation in early postoperative period of isolated coronary artery bypass grafting. Annals of the Russian Academy of Medical Sciences, 70(3), pp.273–278. https://doi.org/10.15690/vramn.v70i3.1322 (In Russian)

Hohnloser, S.H., Crijns, H.J., van Eickels, M., Gaudin, C., Page, R.L. and Torp-Pedersen, C. et al. (2009). Effect of dronedarone on cardiovascular events in atrial fibrillation. New England Journal of Medicine, 360(7), pp.668–678. https://doi.org/10.1056/NEJMoa0803778

Patel, M.R., Mahaffey, K.W., Garg, J., Pan, G., Singer, D.E., Hacke, W. et al. (2011). Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. New England Journal of Medicine, 365(10), pp.883–891. https://doi.org/10.1056/NEJMoa1009638

Connolly, S.J., Ezekowitz, M.D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A. et al. (2009). Dabigatran versus warfarin in patients with atrial fibrillation. New England Journal of Medicine, 361(12), pp.1139–1151. https://doi.org/10.1056/NEJMoa0905561

Van Gelder, I.C., Groenveld, H.F., Crijns, H.J., Tuininga, Y.S., Tijssen, J.G., Alings, A.M. et al. (2010). Lenient versus strict rate control in patients with atrial fibrillation. New England Journal of Medicine, 362(15), pp.1363–1373. https://doi.org/10.1056/NEJMoa1001337

Kralev, S., Schneider, K., Lang, S., Süselbeck, T. and Borggrefe, M. (2011). Incidence and severity of coronary artery disease in patients with atrial fibrillation undergoing first-time coronary angiography. PLoS ONE, 6(9), e24964. https://doi.org/10.1371/journal.pone.0024964

 Otterstad, J.E., Kirwan, B.A., Lubsen, J., De Brouwer, S., Fox, K.A., Corell, P. and Poole-Wilson, P.A. (2006). Incidence and outcome of atrial fibrillation in stable symptomatic coronary disease. Scandinavian Cardiovascular Journal, 40(3), pp.152–159. https://doi.org/10.1080/14017430600746268

 Schmitt, J., Duray, G., Gersh, B.J. and Hohnloser, S.H. (2009). Atrial fibrillation in acute myocardial infarction: a systematic review of the incidence, clinical features and prognostic implications. European Heart Journal, 30(9), pp.1038–1045. https://doi.org/10.1093/eurheartj/ehn579

 Jabre, P., Jouven, X., Adnet, F., Thabut, G., Bielinski, S.J., Weston, S.A. and Roger, V.L. (2011). Atrial fibrillation and death after myocardial infarction: a community study. Circulation, 123(19), pp.2094–2100. https://doi.org/10.1161/CIRCULATIONAHA.110.990192